Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYNE-101 in Myotonic Dystrophy Type 1
NCT07486934Phase 3Recruiting
- Sponsor
- Dyne Therapeutics
- Start
- May 2026
- Primary completion
- Jul 2028
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of zeleciment basivarsen in myotonic dystrophy type 1 (DM1) (3 arms), sponsored by Dyne Therapeutics. Primary endpoint: 5 Times Sit-To-Stand Time at Week 49. Started May 2026; status: recruiting.
02
Drugs
zeleciment basivarsen
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT07486934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486934.